Sugi Predict

Sugi Predict / Compounds / SCHEMBL397997

SCHEMBL397997

SCHEMBL397997

[C](=Cc1ccccc1)C=Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.48
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ CYP19A1 P11511 2/20 0.41
▸ MAOA P21397 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ NFE2L2 Q16236 2/20 0.41
▸ TRPA1 O75762 1/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HDAC3 O15379 1/20 0.39
▸ TNKS O95271 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HCAR2 Q8TDS4 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ HDAC10 Q969S8 1/20 0.39
▸ HDAC11 Q96DB2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9490946 0.88 HPGD (0.43) MAOBALDH1A1NFE2L2TRPA1MAPT
SCHEMBL11827359 0.83 TRPA1 (0.67) MAOBMEN1KMT2ACYP19A1ALDH1A1
SCHEMBL5948500 0.78 ALDH1A1 (0.35) MAOBMEN1KMT2ACYP19A1MAOA
SCHEMBL9438651 0.76 MAOB (0.56) MAOBMEN1KMT2ACYP19A1MAOA
SCHEMBL9119896 0.76 MAOB (0.55) MAOBMEN1KMT2ACYP19A1MAOA
SCHEMBL7109627 0.72 MAOB (0.50) MAOBMEN1KMT2ACYP19A1MAOA
SCHEMBL8892833 0.72 ALDH1A1 (0.50) MAOBMEN1KMT2ACYP19A1MAOA
SCHEMBL27745 0.72 MAOB (0.50) MAOBMEN1KMT2ACYP19A1MAOA
SCHEMBL396616 0.72 MAOB (0.50) MAOBMEN1KMT2ACYP19A1MAOA
SCHEMBL6865938 0.72 MAOB (0.50) MAOBMEN1KMT2ACYP19A1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734431-B1 LUBRICANT COMPOSITION CONTAINING A POLYMERIC ANTIOXIDANT EXXON RESEARCH ENGINEERING CO (US) 1998-02-25 — — EP claimed
US-20240047826-A1 Multilayer Porous Separator Film SONG KWANGJIN (US) 2024-02-08 — — US disclosed
CN-112930369-A Polypropylene composition with excellent rigidity and impact strength 阿布扎比聚合物有限公司(博禄) 2021-06-08 — — CN disclosed
US-10363546-B2 Multilayer polymeric membrane Liso Plastics LLC (US) 2019-07-30 — — US disclosed
US-20180065105-A1 MULTILAYER POLYMERIC MEMBRANE AND PROCESS LiSo Plastics, L.L.C. (US) 2018-03-08 — — US disclosed
US-20180043656-A1 Oriented Multilayer Porous Film LiSo Plastics, L.L.C. (US) 2018-02-15 — — US disclosed
US-9865823-B2 Quinolinium dyes with fluorinated counter anion for dye sensitized solar cells BASF SE (DE) 2018-01-09 — — US disclosed
US-9669032-B2 Enhanced treatment regimens using mTOR inhibitors INTELLIKINE LLC (US) 2017-06-06 — — US disclosed
US-9345706-B2 Benzoxazole kinase inhibitors and methods of use INTELLIKINE, LLC (US) 2016-05-24 — — US disclosed
US-20160038497-A1 Enhanced Treatment Regimens Using mTOR Inhibitors FAETH THERAPEUTICS, INC. 2016-02-11 — — US disclosed
US-8101613-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-01-24 — — US disclosed
EP-2383248-A1 Process for the preparation of beta-chlorovinyl ketones Lonza Ltd. (CH) 2011-11-02 — — EP disclosed
EP-2365750-A1 BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE Intellikine, Inc. (US) 2011-09-21 — — EP disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 — — US disclosed
EP-2308879-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2011-04-13 — — EP disclosed
EP-2305682-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2011-04-06 — — EP disclosed
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-03-31 — — US disclosed
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. 2011-02-24 — — US disclosed
US-7662844-B2 Naphthylene derivatives as cytochrome P450 inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-02-16 — — US disclosed
WO-1997000249-A1 HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE MAP3K20, MAP3K1, PDPK1 MAOB 3091/4885MEN1 3187/4885KMT2A 968/4885
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE MTOR, PDPK1, PIKFYVE MAOB 2532/4885MEN1 2706/4885KMT2A 914/4885
US-20160038497-A1 Enhanced Treatment Regimens Using mTOR Inhibitors RICTOR, MTOR, RPTOR MAOB 4542/4885MEN1 1442/4885KMT2A 929/4885
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS IGF1R, IGFBP3, INSR MAOB 2051/4885MEN1 1371/4885KMT2A 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.